Article Dans Une Revue Clinical Pharmacokinetics Année : 2017

Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group

Anne-Laure Gagez
  • Fonction : Auteur

Résumé

Rituximab is an anti-CD20 monoclonal antibody approved in the first-line treatment of patients with chronic lymphocytic leukemia (CLL). Rituximab pharmacokinetics shows a time dependency possibly related to changes in the target antigen amount over time. The purpose of this study was to quantify the influence of both CD20 antigenic mass and the FcγRIIIA genetic polymorphism on rituximab pharmacokinetics in CLL.

Domaines

Fichier principal
Vignette du fichier
tout2016.pdf (460.99 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Licence

Dates et versions

hal-01769807 , version 1 (15-01-2024)

Licence

Identifiants

Citer

Mira Tout, Anne-Laure Gagez, Stéphane Lepretre, Valérie Gouilleux-Gruart, Nicolas Azzopardi, et al.. Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. Clinical Pharmacokinetics, 2017, 56 (6), pp.635 - 647. ⟨10.1007/s40262-016-0470-8⟩. ⟨hal-01769807⟩
238 Consultations
201 Téléchargements

Altmetric

Partager

  • More